VBI Vaccines, Inc. (VBIV)
Stock Price:
$2.47 USD
0.01 (0.49%)
Updated Oct 27, 2020 12:18 PM EDT - Market open
Key Info
| Market Cap |
571.52M |
| Revenue (ttm) |
1.82M |
| Net Income (ttm) |
-44.91M |
| Shares Out |
231.20M |
| EPS (ttm) |
-0.27 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$2.47 |
| Previous Close |
$2.46 |
| Change ($) |
0.01 |
| Change (%) |
0.49% |
| Day's Open |
2.47 |
| Day's Range |
2.38 - 2.49 |
| Day's Volume |
1,095,309 |
| 52-Week Range |
0.53 - 6.93 |
More Stats
| Market Cap |
571.52M |
| Enterprise Value |
502.67M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
231.20M |
| Float |
209.54M |
| EPS (basic) |
-0.26 |
| EPS (diluted) |
-0.27 |
| FCF / Share |
-0.18 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
37.33M |
| Short Ratio |
4.59 |
| Short % of Float |
17.81% |
| Beta |
1.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
314.02 |
| PB Ratio |
4.77 |
| Revenue |
1.82M |
| Operating Income |
-43.87M |
| Net Income |
-44.91M |
| Free Cash Flow |
-38.90M |
| Net Cash |
68.85M |
| Net Cash / Share |
0.30 |
| Gross Margin |
-312.25% |
| Operating Margin |
-2,410.22% |
| Profit Margin |
-2,467.50% |
| FCF Margin |
-2,137.53% |
| ROA |
-17.03% |
| ROE |
-44.27% |
| ROIC |
-366.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.75*
(173.06% upside)
Low
3.00
Current: $2.47
High
9.00
Target: 6.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 2.22 | 3.36 | 0.87 | 0.55 | 0.96 |
| Revenue Growth | -33.8% | 287.86% | 57.85% | -42.62% | - |
| Gross Profit | -5.68 | -1.15 | -4.33 | -3.12 | -2.80 |
| Operating Income | -52.40 | -60.41 | -37.28 | -24.85 | -23.76 |
| Net Income | -54.81 | -63.60 | -39.00 | -23.21 | -26.19 |
| Shares Outstanding | 119 | 65.65 | 44.16 | 30.04 | 12.63 |
| Earnings Per Share | -0.46 | -0.97 | -0.88 | -0.77 | -2.07 |
| Operating Cash Flow | -48.71 | -45.53 | -31.38 | -18.52 | -9.09 |
| Capital Expenditures | -3.67 | -5.99 | -0.64 | -0.59 | -0.58 |
| Free Cash Flow | -52.39 | -51.53 | -32.02 | -19.10 | -9.68 |
| Cash & Equivalents | 44.21 | 59.27 | 67.69 | 32.28 | 12.48 |
| Total Debt | 16.30 | 14.03 | 13.14 | 11.96 | - |
| Net Cash / Debt | 27.91 | 45.24 | 54.56 | 20.33 | 12.48 |
| Assets | 122 | 138 | 146 | 105 | 17.05 |
| Liabilities | 33.95 | 39.47 | 25.87 | 188 | 4.85 |
| Book Value | 88.26 | 98.13 | 120 | -83.73 | 12.19 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
VBI Vaccines, Inc. |
| Country |
United States |
| Employees |
123 |
| CEO |
Jeffrey R. Baxter |
Stock Information
| Ticker Symbol |
VBIV |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: VBIV |
Description
VBI Vaccines, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.